Novel FLCN Mutations and mRNA Rescue in Birt-Hogg-Dubé Syndrome: Insights from a Recent Study

Study Background and Research Question

Birt-Hogg-Dubé (BHD) syndrome is a rare autosomal dominant disorder characterized by lung cysts, spontaneous pneumothorax, cutaneous fibrofolliculomas, and renal neoplasms. Its genetic basis lies in pathogenic variants of the folliculin (FLCN) gene, a tumor suppressor located on chromosome 17p11.2. While over 200 FLCN mutations have been reported, the mutational spectrum is ethnically heterogeneous and genotype–phenotype correlations remain incompletely defined. Current management for BHD is largely supportive, with a pressing need for disease-modifying therapies. The reference study (Therapeutic Advances in Respiratory Disease, 2026) sought to characterize clinical and genetic features of BHD in two Chinese families and to evaluate the feasibility of mRNA-based restoration of FLCN function as a potential therapeutic approach.

Key Innovation from the Reference Study

The principal innovation lies in the dual advances reported: (1) the identification and functional characterization of a novel nonsense mutation (p.Q44*) and reclassification of a previously ambiguous missense variant (p.W376R) as pathogenic; and (2) the demonstration that exogenous delivery of synthetic FLCN mRNA can rescue FLCN protein expression and normalize mTORC1 pathway dysregulation in vitro. This is one of the first studies to functionally validate mRNA supplementation as a corrective strategy for FLCN loss-of-function in BHD, directly addressing a critical translational gap.

Methods and Experimental Design Insights

The study adopted a family-based prospective cohort design, enrolling two unrelated Chinese families with suspected BHD syndrome. The experimental workflow included:

• Genetic analysis: Whole-exome sequencing (WES) to pinpoint candidate mutations in probands, followed by Sanger sequencing for variant validation and co-segregation analysis among family members.
• Bioinformatic assessment: Computational modeling to predict structural and functional consequences of the missense variant (p.W376R).
• In vitro functional assays: HEK293T cells were transfected with either wild-type FLCN, mutant FLCN (p.W376R and p.Q44*), or empty vector. To test mRNA-based rescue, synthetic FLCN mRNA was co-transfected with mutant constructs.
• Expression and signaling analysis: Quantitative PCR and immunoblotting were used to measure FLCN protein levels and to assess mTORC1 pathway activity (a known FLCN effector mechanism).

Protocol Parameters

• Whole-exome sequencing: Performed on genomic DNA extracted from blood; proband and available relatives sequenced for co-segregation.
• Plasmid and mRNA transfection: HEK293T cells seeded 24 hours prior; plasmid DNA (wild-type, p.W376R, p.Q44* constructs) or synthetic FLCN mRNA introduced using standard transfection reagents at concentrations empirically optimized for maximal expression.
• mTORC1 pathway assay: Phosphorylation status of downstream effectors (e.g., S6K1) measured by immunoblotting 24–48 hours post-transfection.
• Variant pathogenicity evaluation: ACMG guidelines for variant classification integrated with family co-segregation and in vitro functional data.

Core Findings and Why They Matter

Several important discoveries emerge from this work:

• Clinical heterogeneity: Despite confirmed FLCN mutations, affected individuals in both families mainly exhibited respiratory symptoms, without the classical skin or renal findings, underscoring the variable expressivity of BHD syndrome in different populations (reference study).
• Genetic findings: WES identified a novel nonsense mutation (p.Q44*) and a missense variant (p.W376R) previously classified as a variant of uncertain significance (VUS). Family co-segregation analyses and bioinformatics predicted both mutations to be pathogenic.
• Functional evidence: Both FLCN mutations led to reduced FLCN protein expression in HEK293T cells, resulting in mTORC1 hyperactivation—consistent with loss of tumor suppressor function.
• mRNA-based rescue: Transfection of synthetic FLCN mRNA restored FLCN protein levels and reversed mTORC1 pathway dysregulation in mutant-expressing cells. This provides a proof-of-principle that mRNA supplementation could be therapeutically beneficial in BHD patients harboring loss-of-function mutations.

These results expand the known FLCN mutational repertoire and establish functional mRNA supplementation as a rational direction for future therapy development. The reclassification of p.W376R as pathogenic also informs genetic counseling and risk assessment in BHD-affected families.

Limitations and Transferability

While the reference study provides rigorous genetic and in vitro functional evidence, it is subject to several limitations:

• Sample size: Only two families were studied; broader screening is needed to generalize findings across diverse populations.
• In vitro model: The rescue of FLCN function was demonstrated in HEK293T cells, which may not fully recapitulate tissue-specific disease mechanisms, especially in lung or renal tissue.
• Therapeutic translation: The delivery, stability, and immunogenicity of synthetic mRNA in vivo remain untested in BHD, and the long-term effects of mRNA-based protein replacement require further study.

Despite these caveats, the evidence supports the feasibility of using mRNA-based strategies for genetic disorders characterized by haploinsufficiency or loss-of-function mutations, and it lays the groundwork for future translational research.

Why this cross-domain matters, maturity, and limitations

The use of synthetic mRNA to rescue protein expression in monogenic diseases has gained momentum following the clinical success of mRNA vaccines. This cross-domain application—from infectious disease to rare genetic syndromes—carries substantial promise, though it remains in preclinical stages for BHD syndrome. The main maturity gap is in vivo validation and clinical safety/efficacy demonstration. However, the reference study’s findings are a key step in bridging molecular genetics and RNA-based therapeutics in rare disease contexts.

Comparison with Existing Internal Articles

At present, there are no existing internal resources or articles within the APExBIO knowledge base directly addressing FLCN mutation intervention or mRNA-based rescue in BHD syndrome. However, related workflows—such as RNA interference experiments, antisense RNA production, and RNA vaccine synthesis—share core technological principles with the mRNA supplementation strategy validated in this study. Future internal articles may expand on RNA delivery and functional rescue in genetic disease models, building on the foundation established by these findings.

Research Support Resources

Researchers aiming to reproduce or extend mRNA-based rescue strategies—whether for BHD syndrome or analogous genetic disorders—require reliable in vitro transcription resources. The HyperScribe™ T7 High Yield RNA Synthesis Kit Plus (SKU K1401) from APExBIO is designed for efficient, high-yield synthesis of capped or modified RNA suitable for transfection studies, mRNA rescue, and related applications. Its robust T7 RNA polymerase system supports workflows such as ribozyme biochemistry, RNA interference experiments, and antisense RNA production, making it a practical resource for translational research on RNA-based interventions.